Scientists have just demonstrated that a treatment called "aleglitazar" has had multiple beneficial effects on cirrhotic rats. Around 700,000 people suffer from cirrhosis of the liver in France, 30% of whom have reached the severe stage of the disease.
The increased pressure in the veins leading to the liver, known as portal hypertension (PH), accounts for the majority of medical complications and deaths associated with cirrhosis. It is manifested by exaggerated vision of the superficial veins of the abdomen (called collateral venous circulation), accumulation of fluid in the abdomen (called ascites), and enlargement of the spleen (or splenomegaly) . In addition, it is responsible for the formation of oesophageal varices, the rupture of which can cause serious gastrointestinal bleeding. Researchers have discovered a promising new approach to treating cirrhosis of the liver.
As their study published in The American Journal of Pathology, scientists tested aleglitazar treatment in cirrhotic rats with portal hypertension. After 21 days of medication, this treatment has notably reduced inflammation, angiogenesis *, tissue damage and fibrosis * associated with cirrhosis of animals.
Control simultaneously the numerous anomalies associated with syndromes
"Aleglitazar is also able to regulate circulating hepatic cirrhotic rats with PH syndrome," says study author Ying-Ying Yang, adding: "Overall, our results indicate that treatment with aleglitazar may be a promising approach to cirrhosis of the liver, as it helps to simultaneously control the many abnormalities associated with PH syndromes of liver cirrhosis ". In patients with cirrhosis, a new study has also proven the efficacy of long-term administration of human albumin.
Human albumin solutions are not a medicine but a cure. They are prepared from a mixture of blood, plasma, serum or placental tissue taken from healthy donors.
Researchers followed 431 patients suffering from cirrhosis from April 2, 2011 to May 27, 2015. One group received standard medical treatment, while a second group received standard medical treatment combined with albumin administration. human (40 g twice a week for 2 weeks, then 40 g a week). Both treatments lasted 18 months.
Results: Overall survival at 18 months was significantly higher in the group with standard medical treatment with human albumin administration. These patients were 38% less likely to die than those who had only received standard medical treatment.
Excessive and prolonged consumption of alcohol
Cirrhosis of the liver is a disease we do not often talk about, but which is common in France. Approximately 700,000 people have cirrhosis, 30% of whom have reached the severe stage of the disease. It is estimated that the number of deaths associated with it is between 10,000 and 15,000 each year. Diagnosis occurs on average at the age of 50 years.
The risk factors for cirrhosis are well identified. The excessive and prolonged consumption of alcohol, the chronic infections by the virus of hepatitis B and the hepatitis C, as well as the metabolic syndrome are indeed responsible for more than 90% of the cases. The other cases are related to genetic hemochromatosis or to autoimmune liver diseases such as primary biliary cirrhosis.
* Formation of new blood vessels that can supply certain cancers.
* Disruption of the healing process.